Question to the Department of Health and Social Care:

To ask Her Majesty's Government what assessment they have made of the use of Evusheld by other countries; and what data they have received on that drug’s efficiency at combatting the effects of COVID-19.

The Antivirals and Therapeutics Taskforce engages with other nations on the use, deployment and evaluation of therapeutics and antivirals. We understand that more than 20 countries have procured Evusheld and a proportion have begun to deploy the treatment.

AstraZeneca announced positive trial data from the PROVENT trial, which showed Evusheld’s efficacy against developing symptomatic COVID-19. However, this trial took place prior to the emergence of the Omicron variant. The TACKLE study will provide additional efficacy data on Evusheld for the treatment of COVID-19. AstraZeneca commissioned the UK Health Security Agency to undertake testing into the effectiveness of Evusheld against the Omicron variants. Initial data against BA.1 and BA.2 has been shared with AstraZeneca. The Department is currently reviewing the efficacy of Evusheld for prophylaxis.